FDA review gives Virpax go-ahead for pain relief candidates 26-Feb-2019 By Ben Hargreaves A pre-IND review by the US FDA has allowed Virpax to continue with NDAs for DSF100 and LBL100, two pain relief products with specialised drug delivery formulations.